Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Bromantane and PE-22-28 — mechanism, side effects, legal status, and pricing.
Bromantane (Ladasten) is a synthetic adamantane-derivative small molecule — not a peptide — developed in Russia as an "actoprotector"/adaptogen with combined mild psychostimulant and anxiolytic activity. It is an approved prescription drug in Russia (Ladasten) for asthenic disorders, but it has no FDA or EMA approval and no blinded, placebo-controlled human trials. It is prohibited in sport (WADA S6 stimulant) and circulates on the gray market as a research chemical.
PE-22-28 is a 7-amino-acid synthetic analog of spadin, a peptide fragment (residues 22-28) of the 44-aa propeptide (PE) released during post-translational maturation of sortilin (the neurotensin receptor-3). It is studied in preclinical models as a fast-acting antidepressant that works by selectively blocking the TREK-1 two-pore potassium channel. There is no established use for hair growth — that is a separate compound and the two should not be confused.
Bromantane
PE-22-28
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Bromantane
No pricing data yet.
Check Bromantane prices →PE-22-28
COA corpus from Disclosed Labs — independently tested batches only.
Bromantane
4
COAs
99.9%
Avg purity
3
Labs
PE-22-28
13
COAs
99.6%
Avg purity
7
Labs
Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.
Key references
Mazella, Borsotto and colleagues at Nice, France identified spadin (Mazella et al., PLoS Biology 2010, PMID 20405001) and subsequently developed shortened PE 22-28 analogs with ~300× improved TREK-1 affinity and longer in vivo half-life (Djillani et al., Front Pharmacol 2017, PMID 28955242). In mouse antidepressant assays (forced swim, tail suspension, novelty-suppressed feeding), acute or 4-day IP dosing at ~3–4 μg/kg produced effects comparable to chronic SSRI treatment; oral gavage at 1 mg/kg was also active. The G/A-PE 22-28 modification extended duration of action to ~21–23 hours. Chronic dosing did not produce cardiac or seizure signals in rodents. No human clinical trials have been conducted. A detailed review of TREK-1 blockers for depression is available in Djillani et al., Pharmacol Ther 2019 (PMID 30291907).
Bromantane and PE-22-28 are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs